8-K
LeonaBio, Inc. Announces Exercisability of Series A Common Warrants
8-K
LeonaBio, Inc. Announces Enrollment of 500th Subject in Phase 3 ELAINE-3 Clinical Trial
8-K
LeonaBio Reports Second Quarter 2026 Financial Results and Business Update
8-K
LeonaBio, Inc. Announces Results of 2026 Annual Meeting of Stockholders
8-K
LeonaBio Reports Q1 2026 Financial Results and Provides Pipeline Updates
8-K/A
Amendment Details Acquisition and Increased Expenditure Plans for ELAINE-3 Study; Enrollment Completion Expected by Q4 2026
